UBS Group’s Inhibikase Therapeutics IKT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $75.4K | Sell |
38,674
-6,592
| -15% | -$12.9K | ﹤0.01% | 6185 |
|
|
2025
Q1 | $99.1K | Buy |
45,266
+17,740
| +64% | +$38.9K | ﹤0.01% | 5790 |
|
|
2024
Q4 | $89.5K | Buy |
27,526
+22,653
| +465% | +$73.6K | ﹤0.01% | 5726 |
|
|
2024
Q3 | $6.34K | Buy |
+4,873
| New | +$6.34K | ﹤0.01% | 6768 |
|
|
2024
Q2 | – | Sell |
-3,214
| Closed | -$6.94K | – | 8531 |
|
|
2024
Q1 | $6.94K | Buy |
+3,214
| New | +$6.94K | ﹤0.01% | 6253 |
|
|
2023
Q4 | – | Sell |
-149
| Closed | -$207 | – | 8301 |
|
|
2023
Q3 | $207 | Buy |
+149
| New | +$207 | ﹤0.01% | 7555 |
|
|
2023
Q1 | – | Sell |
-22
| Closed | -$65 | – | 8714 |
|
|
2022
Q4 | $65 | Sell |
22
-1,228
| -98% | -$3.63K | ﹤0.01% | 9250 |
|
|
2022
Q3 | $7K | Buy |
+1,250
| New | +$7K | ﹤0.01% | 7771 |
|
|
2022
Q2 | – | Sell |
-852
| Closed | -$8K | – | 9464 |
|
|
2022
Q1 | $8K | Buy |
852
+559
| +191% | +$5.25K | ﹤0.01% | 7614 |
|
|
2021
Q4 | $3K | Sell |
293
-1,132
| -79% | -$11.6K | ﹤0.01% | 8532 |
|
|
2021
Q3 | $16K | Buy |
+1,425
| New | +$16K | ﹤0.01% | 6278 |
|